Treatment Philosophy for Inhalant Allergy— Key Concepts George F. Kroker MD FACAAI.

Slides:

Advertisements

Similar presentations

Food Allergy Update Thomas Flaim, M.D.. Prevalence of Food Allergy Prevalence rate is 6% in children < 3 years of age; 4% in adults Prevalence rate is.

Advertisements

Importance of Vaccine Safety Decreases in disease risks and increased attention on vaccine risks Public confidence in vaccine safety is critical Low tolerance.

Agency for Healthcare Research and Quality (AHRQ)

4 월 4 일 ( 금 ) PROGRAM [ Clavel Hall ] Postgraduate Course : Food Allergy 1. Food Allergy Animal Model 아주의대 이수영 2. Food Allergy and Gut 인하의대 김정희 3. Diagnosis.

Use of Multiple Allergen Mixes in Immunotherapy Harold S. Nelson, MD Professor of Medicine National Jewish Health University of Colorado Denver School.

Exercise Management Cancer. Pathophysiology Cancer is not a single disease; it is a collection of hundreds of diseases that share the common feature of.

Allergy Allergy is caused by an improper reaction of our immune system to certain factors. There are two basic types of hypersensitiveness: -early type.

1 Assessing and Improving ARV Adherence HAIVN Harvard Medical School AIDS Initiative in Vietnam.

CHEE DRUG PRODUCT DEVELOPMENT u Drug ä agent intended for use in the diagnosis, mitigation, treatment, cure, or prevention of disease in man or animals.

SLIT: dealing with trouble, doing it right. Giovanni B Pajno MD Professor of Pediatrics Department of Pediatrics – Allergy Unit University of Messina Italy.

EVALUATION OF THREE ALLERGEN SPECIFIC IMMUNOTHERAPY METHODS Standard Injection RUSH Injection Sublingual Abstract# 54 Richard Herrscher M.D. FACAAI Clinical.

How do we help?. Providing education for children that normally would not receive any.

Asthma Management and the Allergist: Better Outcomes at Lower Cost.

Which Patients for Subcutaneous Immunotherapy? Harold S. Nelson. MD Professor of Medicine National Jewish Heath University of Colorado Denver School of.

SLIT and Atopic Dermatitis George F. Kroker, MD ©2008 Allergychoices, Inc. All Rights Reserved.

You Can Never Stop a Biologic

1 Robert J. Spiegel, M.D. Sr. V. P. Medical Affairs Chief Medical Officer Schering Plough FDA ADVISORY COMMITTEE 5/11/01.

Vincent S. Beltrani, MD, FAAAAI Board Certified by American Academy of Dermatology American Academy Allergy, Asthma & Immunology Associate Clinical Professor.

Options for Preventing Anthrax After Exposure: Summary for Clinicians & Public Health Officials Julie Louise Gerberding, MD, MPH Acting Deputy Director.

Sublingual Allergy Treatment. Sublingual Immunotherapy Immunotherapy is widely used by allergy specialists because it treats the underlying cause of allergic.

Safe Prescribing of Opioids for the Management of Chronic Nonterminal Pain La Tanya Austin, PGY3.

The PRECIS-2 tool: Matching Intent with Methods David Hahn, MD, MS, WREN Director Department of Family Medicine & Community Health University.

Sublingual Immunotherapy

Mark S. La Shell, MD, Christopher W. Calabria, MD, James M. Quinn, MD

Recognition and First-Line Treatment of Anaphylaxis

Anaphylaxis: Recent advances in assessment and treatment

The Journal of Allergy and Clinical Immunology: In Practice

“Inflammatory skin march”: IL-1–mediated skin inflammation, atopic dermatitis, and psoriasis to cardiovascular events Keiichi Yamanaka, MD, PhD, Hitoshi.

Efficacy of Inhalational Nitric Oxide Therapy in the Clinical Management of Persistent Pulmonary Hypertension of the Newborn John P. Kinsella, M.D.,

Copyright © 2007 American Medical Association. All rights reserved.

Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,

Jessica P. Hollenbach, PhD, Michelle M. Cloutier, MD

Clinical Pharmacokinetics

Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.

Protective effect of inhaled budesonide against unlimited airway narrowing to methacholine in atopic patients with asthma Patrick Booms, MSca, David.

Eli O. Meltzer, MD, Michael S. Blaiss, MD, M

Implementing Best Practices in the Management of Allergic Diseases

The Future of House Dust Mite Allergy

Network Meta-analysis Shows Commercialized Subcutaneous and Sublingual Grass Products Have Comparable Efficacy Harold Nelson, MD, Shannon Cartier, MSc,

Advances in Peanut Allergen Immunotherapy

World Allergy Organization anaphylaxis guidelines: Summary

In-Depth Discussion of Key Data on Immunotherapy for Allergic Diseases

Management of Systematic Lupus Erythematosus

به نام آنكه هستي نام ازويافت فلك جنبش.زمين آرام ازويافت

Advances in Peanut Allergy

Noninjection routes for immunotherapy

Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? O.A. Cornely Clinical Microbiology and.

Paul M. O’Byrne, MB, FRCPI, FRCP(C)a, Soren Pedersen, MD, PhDb

Safety and outcomes of aspirin desensitization for aspirin-exacerbated respiratory disease: A single-center study Jeremy Waldram, MD, Kristen Walters,

Can we produce true tolerance in patients with food allergy?

Phillip Lieberman, MD, David Golden, MD

Linda S. Cox, MD, Cheryl Hankin, PhD, Richard Lockey, MD

Justin R. Chen, MD, Brett L. Buchmiller, MD, David A. Khan, MD

Insect sting allergy and venom immunotherapy: A model and a mystery

Sharon Seth, MD, David A. Khan, MD

Children's compliance with allergen immunotherapy according to administration routes Giovanni Battista Pajno, MD, Daniela Vita, MD, Lucia Caminiti, MD,

Mark S. La Shell, MD, Christopher W. Calabria, MD, James M. Quinn, MD

POINT: Should Inhaled Antibiotic Therapy Be Used Routinely for the Treatment of Bacterial Lower Respiratory Tract Infections in the ICU Setting? Yes

Corticosteroids in the treatment of pediatric allergic rhinitis

Margaret B. Nolan, MD, David O. Warner, MD Mayo Clinic Proceedings

Volume 128, Issue 4, Pages (April 2005)

9. Anaphylaxis Journal of Allergy and Clinical Immunology

Fiftieth Annual Meeting of the American Academy of Allergy and Immunology: Anaheim, California, March 1994 Lawrence M. Lichtenstein, MD, PhD Journal.

Ernesto Bosch, M. D. , Elena Labarta, M. D

Presentation transcript:

Treatment Philosophy for Inhalant Allergy— Key Concepts George F. Kroker MD FACAAI

Copyright 2014 Allergy Associates of La Crosse David Morris M.D.

Copyright 2014 Allergy Associates of La Crosse Inhalant Allergy Treatment  Immunotherapy (SCIT or SLIT) is the only therapy considered to be disease- modifying for the treatment of inhalant allergy

Copyright 2014 Allergy Associates of La Crosse Why Treat Inhalant Allergy? The LCM Philosophy  Simple avoidance often not possible  Immunotherapy is only disease- modifying tool available  Helps stop the atopic march in children  Important part of total load  Improves quality of life

Copyright 2014 Allergy Associates of La Crosse Inhalant Allergy Axioms  Inhalant Allergies may affect any mucosal system—respiratory, gastrointestinal, vaginal, as well as dermal  Different allergy conditions require different dosing schedules to achieve optimum results  Inhalant allergy should never be viewed in isolation, but as part of a bigger picture in the allergy patient

Copyright 2014 Allergy Associates of La Crosse Total Load Concept

Copyright 2014 Allergy Associates of La Crosse The La Crosse Protocol  Clinical efficacy  Used in treating multiple patients over many years  Safety  Versatility  Cost-effectiveness  Supported by medical literature

Copyright 2014 Allergy Associates of La Crosse AAOA & La Crosse Protocols: Comparisons--Experience AAOA Protocol La Crosse Protocol Clinical Experience 6 years (approx)40+ years Number of Patients Rx’ed Several thousand(?) 140,000+ patients (2013) Dose/FrequencyHi dose Low Frequency Lower Dose Higher Frequency

Copyright 2014 Allergy Associates of La Crosse AAOA & La Crosse Protocols: Comparisons--Comprehensiveness AAOA Protocol La Crosse Protocol Initial DoseStandard, based on qualitative testing Optimized with IDT Delayed inhalant Food Allergy Rx Not in ProtocolIn Protocol Number of Antigens Limited to <10Not limited to <10

Copyright 2014 Allergy Associates of La Crosse AAOA & La Crosse Protocols: Comparisons--Versatility/Safety AAOA Protocol La Crosse Protocol Protocol Flexibility“One Size Fits All”“A Family of dosing Protocols” SafetyHigher risk of side effects Lower risk of side effects CostHigher cost for larger antigen amt Lower cost for lower antigen amt

Copyright 2014 Allergy Associates of La Crosse The La Crosse Method is a Family of Dosing Protocols  Protocol for multiple inhalant/food allergies (“threshold dosing”)  Protocol for monosensitized pollen allergy (“hi dose preseasonal”)  Protocol for delayed onset allergy  Protocol for treating food anaphylaxis

Copyright 2014 Allergy Associates of La Crosse Thank you